Login / Signup

Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.

David Bernard MiklosMohammad Abu ZaidJulian P CooneyJörn C AlbringMary Evelyn FlowersAlan P SkarbnikIbrahim Yakoub-AghaBor-Sheng KoBenedetto BrunoEdmund K WallerJean A YaredSang Kyun SohnClaude-Eric BulaboisTakanori TeshimaDavid JacobsohnHildegard GreinixAhmad MokatrinYihua LeeJustin T WahlstromLori StylesGerard Sociè
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
There was no statistical difference observed in the primary and secondary end points with ibrutinib-prednisone treatment. No new safety signals were observed with ibrutinib treatment in previously untreated patients with cGVHD. The primary end point of iNTEGRATE was not met.
Keyphrases
  • phase iii
  • open label
  • double blind
  • clinical trial
  • chronic lymphocytic leukemia
  • randomized controlled trial
  • tyrosine kinase
  • replacement therapy
  • smoking cessation